文献速递哮喘

奥马珠单抗降低非特应性哮喘患者支气管黏膜 IgE 并改善肺功能

Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma.
PubMed 文献 · Eur Respir J · 2016-10-20

这项随机对照研究纳入 18 例有症状的非特应性哮喘患者,按 1:1 接受奥马珠单抗或相同安慰剂治疗 20 周。奥马珠单抗显著降低支气管黏膜总 IgE+ 细胞中位数(p<0.01),并在常规治疗被监督下大幅减量后使 FEV1 绝对值和 % 预计值优于安慰剂(p=0.04 和 p=0.015)。

要点

  • 奥马珠单抗可显著降低非特应性哮喘患者支气管黏膜 IgE+ 细胞中位数(p<0.01)。
  • 常规治疗减量 destabilise 后,奥马珠单抗组 FEV1 绝对值(p=0.04)和 % 预计值(p=0.015)均优于安慰剂。
  • 奥马珠单抗未显著改变黏膜总肥大细胞、浆细胞、B 淋巴细胞、嗜酸性粒细胞和浆母细胞中位数。

核心结论

  • 奥马珠单抗治疗非特应性哮喘可减少支气管黏膜 IgE+ 肥大细胞,并在停减常规治疗时改善肺功能。

研究设计与样本

  • 随机对照研究,18 例有症状的非特应性哮喘患者按 1:1 随机接受奥马珠单抗或相同安慰剂,在原有治疗基础上治疗 20 周。
  • 治疗 12-14 周前后采集支气管活检,随后监督下大幅减少常规治疗使病情 destabilise,主要结局为 12-14 周支气管黏膜 IgE+ 细胞变化及 20 周减量后 FEV1 变化。

主要发现

  • 奥马珠单抗组支气管黏膜总 IgE+ 细胞中位数显著降低(p<0.01),安慰剂组无此变化。
  • 奥马珠单抗未显著改变黏膜总肥大细胞、浆细胞、B 淋巴细胞、嗜酸性粒细胞和浆母细胞中位数,浆母细胞因呈分散簇状难以计数。
  • 20 周时安慰剂组肺功能下降而奥马珠单抗组改善,FEV1 绝对值差异 p=0.04,FEV1 % 预计值差异 p=0.015。

临床怎么用

  • 对非特应性哮喘患者,奥马珠单抗可能作为常规治疗减量期间的维持选项,但需结合本研究小样本结果谨慎评估。

局限性

  • 样本量仅 18 例,结果需更大规模研究验证。
  • 浆母细胞因呈分散簇状分布而难以准确计数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Omalizumab therapy of non-atopic asthmatics reduces bronchial mucosal IgE and inflammation and preserves/improves lung function when disease is destabilised by staged withdrawal of therapy.18 symptomatic, non-atopic asthmatics were randomised (1:1) to receive omalizumab or identical placebo treatment in addition to existing therapy for 20 weeks. Bronchial biopsies were collected before and after 12-14 weeks of treatment, then the patients destabilised by substantial, supervised reduction of their regular therapy. Primary outcome measures were changes in bronchial mucosal IgE+ cells at 12-14 weeks, prior to regular therapy reduction, and changes in lung function (forced expiratory volume in 1 s) after destabilisation at 20 weeks. Quality of life was also monitored.Omalizumab but not placebo therapy significantly reduced median total bronchial mucosal IgE+ cells (p<0.01) but did not significantly alter median total mast cells, plasma cells, B lymphocytes, eosinophils and plasmablasts, although the latter were difficult to enumerate, being distributed as disperse clusters. By 20 weeks, lung function declined in the placebo-treated patients but improved in the omalizumab treated patients, with significant differences in absolute (p=0.04) and % predicted forced expiratory volume in 1 s (p=0.015).Omalizumab therapy of non-atopic asthmatics reduces bronchial mucosal IgE+ mast cells and improves lung function despite withdrawal of conventional therapy.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Pillai P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016. PMID: 27824606. doi:10.1183/13993003.01501-2015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。